Compared with EBV+ DLBCL, the recurrent mutation genes for EBV-negative DLBCL were KMT2D (4/6; 66.7%), CREBBP (3/6; 50.0%), PIM1 (2/6; 33.3%), TNFAIP3 (2/6; 33.3%), and BCL2 (2/6; 33.3%). Here, BCL2 is linked to diffuse large B-cell lymphoma.